CoChat

Effects of exenatide twice daily versus sitagliptin on 24‐h glucose, glucoregulatory and hormonal measures: a randomized, double‐blind, crossover study

Open access
Berg, J. K., Shenouda, S. K., Heilmann, C. R., Gray, A. L., Holcombe, J. H. · 2011 · Diabetes, Obesity and Metabolism
Cited by 57

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Aim: To compare exenatide and sitagliptin glucose and glucoregulatory measures in subjects with type 2 diabetes. Methods: An 8‐week, double‐blind, randomized, crossover, single‐centre study. Eighty‐six subjects (58% female, body mass index 35 ± 5 kg/m 2 , haemoglobin A1c 8.3 ± 1.0%) received either exenatide 10 µg (subcutaneous) twice daily or sitagliptin 100 mg (oral) daily for 4 weeks and crossed to the other therapy for an additional 4 weeks. Main outcome was time‐averaged glucose during the 24‐h inpatient visits. Results: Both treatments decreased average 24‐h glucose, but exenatide had a greater effect [between‐group difference: −0.67 mmol/l, 95% confidence interval (CI): −0.9 to −0.4 mmol/l]. Both treatments decreased 2‐h postprandial glucose (PPG), area under the curve of glucose above 7.8 mmol/l (140 mg/dl) and 11 mmol/l (200 mg/dl) and increased the time spent with glucose between 3.9 and 7.8 mmol/l (70 and 140 mg/dl) during 24 h, but exenatide had a significantly greater effect (p < 0.05). Both treatments decreased postprandial serum glucagon, with exenatide having a greater effect (p < 0.005). Both treatments decreased fasting blood glucose to a similar degree (p = 0.766). Sitagliptin increased, while exenatide decreased, postprandial intact glucagon‐like peptide‐1. Both drugs improved homeostasis model assessment of β ‐cell function (HOMA‐B), with exenatide having a significantly greater effect (p = 0.005). Both exenatide and sitagliptin decreased 24‐h caloric intake, with exenatide having a greater effect (p < 0.001). There was no episode of major hypoglycaemia. Adverse events were mild to moderate and mostly gastrointestinal in nature with exenatide. No study withdrawals were due to an adverse event. Conclusion: Compared to sitagliptin, exenatide showed significantly lower average 24‐h glucose, 2‐h PPG, glucagon, caloric intake and improved HOMA‐B.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01428.x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 57

Metadata

Authors
Berg, J. K., Shenouda, S. K., Heilmann, C. R., Gray, A. L., & Holcombe, J. H.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-09-28
Volume
13
Issue
11
Pages
982-989
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2028092672
Cited by
57
References
10
FWCI
7.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of exenatide twice daily versus sitagliptin on 24‐h glucose, glucoregulatory and hormonal measures: a randomized, double‐blind, crossover study. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01428.x
The paper
Berg, J. K., Shenouda, S. K., Heilmann, C. R., Gray, A. L., & Holcombe, J. H. (2011). Effects of exenatide twice daily versus sitagliptin on 24‐h glucose, glucoregulatory and hormonal measures: a randomized, double‐blind, crossover study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01428.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.